Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70225 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Nancy L Bartlett und 20 weiteren Autor:innen. Beteiligte Einrichtung: Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd..
Abstract (Originalsprache)
Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC ( N = 94; median follow‐up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within‐study comparator cohort of mosunetuzumab IV in a similar patient population ( N = 90; median follow‐up: 22.5 months). The co‐primary PK endpoints (C trough and AUC) were met, demonstrating non‐inferior exposure of mosunetuzumab SC versus IV (observed C trough[C3] : geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20–1.61]; AUC 0–84 : GMR 1.06 [90% CI: 0.92–1.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7–84.7); complete response rate, 61.7% (95% CI: 51.1–71.5); median duration of complete response, 34.6 months (95% CI: 20.7–not evaluable [NE]); and median progression‐free survival, 23.7 months (95% CI: 14.6–NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade ≥ 2: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed‐duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety. Trial Registration: www.clinicaltrials.gov : NCT02500407.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
- BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada.
- Jewish General Hospital, Montreal, Quebec, Canada.
- Royal Adelaide Hospital, Adelaide, Australia.
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Norma C Gutierrez, L Elizabeth Budde
Förderung
- F. Hoffmann-La Roche Ltd.
Zitieren
APA
Bartlett, N. L., Sehn, L. H., Assouline, S., Giri, P., Kuruvilla, J., Schuster, S. J., Yoon, S. S., Fay, K., Hess, G., Dreyling, M., Gutierrez, N. C., Cybulski, E., Sabalvaro, F., Penuel, E., Teodoro, V., Tracy, S., Kuruvilla, D., Chen, J., Wiebking, V., …, & Budde, L. E. (2026). Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. American Journal of Hematology. https://doi.org/10.1002/ajh.70225
Vancouver
Bartlett NL, Sehn LH, Assouline S, Giri P, Kuruvilla J, Schuster SJ, et al. Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. American Journal of Hematology. 2026. doi:10.1002/ajh.70225
BibTeX
@article{Bartlett2026,
author = {Bartlett, Nancy L and Sehn, Laurie H and Assouline, Sarit and Giri, Pratyush and Kuruvilla, John and Schuster, Stephen J and Yoon, Sung-Soo and Fay, Keith and Hess, Georg and Dreyling, Martin and Gutierrez, Norma C and Cybulski, Eva and Sabalvaro, Fidelis and Penuel, Elicia and Teodoro, Vanda and Tracy, Samuel and Kuruvilla, Denison and Chen, Joseph and Wiebking, Volker and Wei, Michael C and Budde, L Elizabeth},
title = {Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70225}
}
EUVIMED